Sign in or create an account to add this stock to your watchlist.
About DURECT (NASDAQ:DRRX)
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRRX
CUSIPN/A
Phone408-777-1417
Debt
Debt-to-Equity Ratio0.50
Current Ratio4.61
Quick Ratio4.32
Price-To-Earnings
Trailing P/E Ratio-65.67
Forward P/E Ratio-8.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$49.17 million
Price / Sales6.48
Cash FlowN/A
Price / CashN/A
Book Value$0.19 per share
Price / Book10.37
Profitability
EPS (Most Recent Fiscal Year)($0.03)
Net Income$-3,690,000.00
Net Margins-8.06%
Return on Equity-25.82%
Return on Assets-7.04%
Miscellaneous
Employees93
Outstanding Shares161,710,000
DURECT (NASDAQ:DRRX) Frequently Asked Questions
What is DURECT's stock symbol?
DURECT trades on the NASDAQ under the ticker symbol "DRRX."
How were DURECT's earnings last quarter?
DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings data on Friday, May, 11th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The specialty pharmaceutical company earned $3.49 million during the quarter, compared to analysts' expectations of $4.20 million. DURECT had a negative return on equity of 25.82% and a negative net margin of 8.06%. View DURECT's Earnings History.
When is DURECT's next earnings date?
What price target have analysts set for DRRX?
3 brokerages have issued 12-month price targets for DURECT's stock. Their forecasts range from $2.00 to $3.50. On average, they anticipate DURECT's share price to reach $2.8333 in the next year. View Analyst Ratings for DURECT.
Are investors shorting DURECT?
DURECT saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 2,055,206 shares, an increase of 32.1% from the March 30th total of 1,555,657 shares. Based on an average trading volume of 890,814 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.4% of the shares of the company are short sold.
Who are some of DURECT's key competitors?
Some companies that are related to DURECT include Uniqure (QURE), Zai Lab (ZLAB), Intra-Cellular Therapies (ITCI), Immuron (IMRN), Retrophin (RTRX), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS), Alder BioPharmaceuticals (ALDR), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), Athenex (ATNX), CytomX Therapeutics (CTMX), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR) and Eagle Pharmaceuticals (EGRX).
Who are DURECT's key executives?
DURECT's management team includes the folowing people:
- Dr. Felix Theeuwes, Co-Founder, Chairman & Distinguished Scientist (Age 80)
- Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 61)
- Mr. Matthew J. Hogan, Principal Accounting Officer, CFO & Sec. (Age 58)
- Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 61)
- Mr. Michael H. Arenberg J.D., M.B.A., Sr. VP of Corp. & Bus. Devel.
Has DURECT been receiving favorable news coverage?
News articles about DRRX stock have trended somewhat positive on Sunday, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DURECT earned a media sentiment score of 0.00 on Accern's scale. They also assigned media stories about the specialty pharmaceutical company an impact score of 48.23 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are DURECT's major shareholders?
DURECT's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.10%), Northern Trust Corp (1.00%), Asymmetry Capital Management L.P. (0.47%), Millennium Management LLC (0.42%), Algert Global LLC (0.31%) and Mackay Shields LLC (0.11%). View Institutional Ownership Trends for DURECT.
Which major investors are selling DURECT stock?
Which major investors are buying DURECT stock?
DRRX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Algert Global LLC, Mackay Shields LLC, Engineers Gate Manager LP, MetLife Investment Advisors LLC, Cubist Systematic Strategies LLC and Northern Trust Corp. View Insider Buying and Selling for DURECT.
How do I buy shares of DURECT?
Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DURECT's stock price today?
One share of DRRX stock can currently be purchased for approximately $1.97.
How big of a company is DURECT?
DURECT has a market capitalization of $318.57 million and generates $49.17 million in revenue each year. The specialty pharmaceutical company earns $-3,690,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. DURECT employs 93 workers across the globe.
How can I contact DURECT?
DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.
MarketBeat Community Rating for DURECT (DRRX)
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
DURECT (NASDAQ:DRRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
DURECT (NASDAQ DRRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.70%
Institutional Ownership Percentage: 44.44%
DURECT (NASDAQ DRRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/3/2016 | April Fund L.P. 21 | Major Shareholder | Buy | 95,000 | $1.16 | $110,200.00 | |  |
| 9/26/2016 | April Fund L.P. 21 | Major Shareholder | Buy | 2,500,000 | $1.15 | $2,875,000.00 | | |
| 4/26/2016 | April Fund L.P. 21 | Major Shareholder | Buy | 5,500,000 | $1.25 | $6,875,000.00 | | |
| 4/26/2016 | Dave Hoffmann | Director | Buy | 200,000 | $1.25 | $250,000.00 | 25,000 | |
| 4/26/2016 | Felix Theeuwes | Chairman | Buy | 160,000 | $1.25 | $200,000.00 | | |
| 3/14/2016 | Armand Neukermans | Director | Buy | 18,000 | $1.39 | $25,020.00 | 1,250 | |
| 3/14/2016 | Felix Theeuwes | Chairman | Buy | 70,000 | $1.41 | $98,700.00 | | |
| 3/10/2016 | James E Brown | CEO | Buy | 20,000 | $1.33 | $26,600.00 | 1,764,530 | |
| 1/11/2016 | April Fund Lp 21 | Major Shareholder | Buy | 300,100 | $1.37 | $411,137.00 | | |
| 9/29/2015 | April Fund Ltd 21 | Major Shareholder | Buy | 952,249 | $1.79 | $1,704,525.71 | | |
| 3/10/2015 | Simon X Benito | Director | Buy | 40,000 | $1.81 | $72,400.00 | | |
| 3/9/2015 | Felix Theeuwes | Chairman | Buy | 225,600 | $1.65 | $372,240.00 | | |
| 3/6/2015 | Felix Theeuwes | Chairman | Buy | 380,000 | $1.57 | $596,600.00 | | |
| 11/21/2014 | Felix Theeuwes | Chairman | Buy | 72,700 | $1.00 | $72,700.00 | | |
| 11/20/2014 | Felix Theeuwes | Chairman | Buy | 136,015 | $0.92 | $125,133.80 | | |
| 11/8/2013 | Felix Theeuwes | Chairman | Buy | 714,285 | $1.40 | $999,999.00 | | |
| 9/10/2013 | Felix Theeuwes | Chairman | Buy | 75,000 | $1.20 | $90,000.00 | | |
| 9/9/2013 | Felix Theeuwes | Chairman | Buy | 25,000 | $1.15 | $28,750.00 | | |
| 6/4/2013 | James E Brown | CEO | Buy | 30,000 | $0.80 | $24,000.00 | | |
| 12/12/2012 | Jon S Saxe | Director | Buy | 15,000 | $0.91 | $13,650.00 | | |
| 11/14/2012 | Felix Theeuwes | Chairman | Buy | 100,000 | $1.01 | $101,000.00 | | |
| 8/28/2012 | Jon S Saxe | Director | Buy | 7,810 | $0.97 | $7,575.70 | | |
| 8/23/2012 | Jon S Saxe | Director | Buy | 5,000 | $1.00 | $5,000.00 | | |
(Data available from 1/1/2013 forward)
DURECT (NASDAQ DRRX) News Headlines
| Source: |
|
DURECT (NASDAQ:DRRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
DURECT (NASDAQ:DRRX) Income Statement, Balance Sheet and Cash Flow Statement
DURECT (NASDAQ DRRX) Stock Chart for Sunday, May, 27, 2018
Loading chart…
